Update: Partner accelerates resminostat development
While 4SC focuses on securing the fresh finance and/or partner required to conduct a Phase IIb study for resminostat in liver cancer, its Japanese partner Yakult Honsha has stepped up development of the HDAC inhibitor. Yakult recently moved two Phase I/II trials, for liver and lung cancer, into the proof-of-concept Phase II part (n=>100) in each study. Importantly, the trial design in first-line liver cancer (also seeking to validate the ZFP64 biomarker) is similar to that proposed by 4SC for its US/EU study. Positive data would therefore provide a compelling case for investment/partnering.4SC is a biotechnology company that researches and develops drugs primarily for the treatment of cancer diseases. The Company has special expertise and clinical products in the field of epigenetics. 4SC's compounds aim to enable new therapeutic methods that offer improved efficacy and tolerability compared to the treatments available to date, both as monotherapy and in combination with other drugs. This approach is intended to enhance treatment benefits for affected patients, coupled with improvements to their life expectancy and quality of life. Adjusted for 1- for -5 stock split, April 2015Adjusted for 1- for -5 stock split, April 2015
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.